Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
Marker Therapeutics, Inc. logo

NASDAQ · MRKR

Marker Therapeutics, Inc.

Healthcare · Biotechnology

$1.01

Up+$0.03 (+2.76%)

Updated Nov 5, 2026, 4:22 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
15.39M
P/E ratio
-1.67
Dividend yield
0.00%
52-week range
$0.87 – $1.79
Volume
94.39K
Avg. volume
265.93K

Price performance · MRKR

MRKR price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

MRKR closed at $1.01 after 21 trading sessions, down 2.88% for the selected period.

Last close
$1.01
Period change
-2.88%
Period low
$0.89
Period high
$1.20
Daily close
View OHLC price history
MRKR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$0.99$1.05$0.9875$1.0194.39K
Nov 3, 2026$0.9051$0.9991$0.8928$0.982994.61K
Nov 2, 2026$0.96$0.97$0.88$0.9011265.72K
Oct 30, 2026$1.03$1.04$0.9597$0.9867.56K
Oct 29, 2026$0.99$1.0699$0.9801$1.0172.94K
Oct 28, 2026$0.955$1.07$0.9006$1.0086.93K
Oct 27, 2026$0.92$0.98$0.8901$0.9513103.96K
Oct 26, 2026$0.9487$1.04$0.8708$0.9064217.61K
Oct 23, 2026$1.07$1.12$0.96$0.9601116.81K
Oct 22, 2026$1.17$1.17$1.07$1.0791.56K
Oct 21, 2026$1.16$1.2675$1.13$1.13149.94K
Oct 20, 2026$1.19$1.24$1.11$1.16209.42K
Oct 19, 2026$1.085$1.20$1.05$1.20580.09K
Oct 16, 2026$1.02$1.20$1.00$1.041.15M
Oct 15, 2026$0.9571$0.9595$0.88$0.92120.79K
Oct 14, 2026$0.92$0.95$0.8877$0.890265.81K
Oct 13, 2026$1.03$1.03$0.91$0.9249175.22K
Oct 12, 2026$0.9818$1.03$0.9801$1.01107.78K
Oct 9, 2026$0.93$1.00$0.93$0.971691.22K
Oct 8, 2026$1.04$1.05$0.95$0.95102.3K
Oct 7, 2026$1.03$1.06$1.03$1.0437.47K

Latest MRKR news

The latest Smart Investors Daily articles mentioning MRKR.

Stock researchCompany · Overview

MRKR research

Overview

Company profile and research snapshot.

Company profile

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
MRKR recent ratings
DateFirmRatingTarget
Dec 8, 2025HC Wainwright & Co.Buy—
Apr 1, 2025WBB SecuritiesStrong Buy—
Mar 5, 2025Canaccord GenuityBuy—
Oct 21, 2024Ladenburg ThalmannBuy—
Apr 30, 2024Ladenburg ThalmannBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 19, 2026

Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer

Competitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing T cell platformHOUSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies under an exclusive worldwide license from Baylor College of Medicine for patients with cancer. Today, Marker announced that the Company has been aw

Yahoo · Sep 22, 2026

Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic malignancies and solid tumors, today highlighted the expanded infrastructure, technical expertise and manufacturing capabilities supporting its lead program, MT-601 (neldaleucel), following the combination of Cellipont Bioservices and Kincell Bio to form Kincellis Advanced Therap

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By